Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02542215 · ClinicalTrials.gov registry record · Phase 2
Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy
A Phase 2 study, sponsored by Sucampo Pharma Americas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT02542215: Clinical Trial Phase 2 study, sponsored by Sucampo Pharma Americas.
NCT02542215 is a Phase 2 study that was terminated before completion, run by Sucampo Pharma Americas. The registered enrollment target is 47 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02542215, a Phase 2 study, was terminated before completion, sponsored by Sucampo Pharma Americas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
Treatment for head and neck cancer often involves a combination of chemotherapy and radiation. One of the unfortunate consequences of standard care for head and neck cancer is the development of painful mouth sores, known as oral mucositis. This study will evaluate the use of cobiprostone spray to prevent oral mucositis, when given for the duration of radiation and chemotherapy (RT/CT) standard care.
Interventions
- DRUG Placebo
- DRUG Cobiprostone
- DRUG Standard Care - Chemotherapy
- RADIATION Standard Care - Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Why NCT02542215 stopped before completion
NCT02542215 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02542215 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02542215 about?
NCT02542215 is a clinical study titled "Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy". Treatment for head and neck cancer often involves a combination of chemotherapy and radiation. One of the unfortunate consequences of standard care for head and neck cancer is the development of painful mouth sores, known as oral mucositis. This study will evaluate the use of cobiprostone spray to...
What is the current status of trial NCT02542215?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2015-06. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02542215?
The interventions under investigation include: Placebo (DRUG), Cobiprostone (DRUG), Standard Care - Chemotherapy (DRUG), Standard Care - Radiation (RADIATION).
Who is sponsoring clinical trial NCT02542215?
This trial is sponsored by Sucampo Pharma Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02542215's enrollment target sits among peer trials
47 1283rd of 2000 higher than 715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia